{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T05:53:01Z","timestamp":1715752381450},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,15]]},"DOI":"10.1097\/qai.0b013e3182a4b991","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T21:29:37Z","timestamp":1374701377000},"page":"443-447","source":"Crossref","is-referenced-by-count":5,"title":["Baseline Clinical HIV Genotypes Are a Valid Measure of Transmitted Drug Resistance Within the Treatment-Naive Population"],"prefix":"10.1097","volume":"64","author":[{"given":"Manon","family":"Ragonnet-Cronin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonita E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina S.","family":"Plitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Zahariadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Merks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Sandstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James I.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-3-20210131","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/135965350801302S01","article-title":". Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia.","volume":"13","author":"Abegaz","year":"2008","journal-title":"Antivir Ther"},{"issue":"suppl 2","key":"R2-3-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350801302S03","article-title":". The World Health Organizations global strategy for prevention and assessment of HIV drug resistance.","volume":"13","author":"Bennett","year":"2008","journal-title":"Antivir Ther"},{"issue":"suppl 2","key":"R3-3-20210131","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350801302S11","article-title":". HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.","volume":"13","author":"Nguyen","year":"2008","journal-title":"Antivir Ther"},{"key":"R4-3-20210131","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkn228","article-title":". Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort.","volume":"62","author":"Payne","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R5-3-20210131","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/135965350400900514","article-title":"Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.","volume":"9","author":"Pillay","year":"2004","journal-title":"Antivir Ther"},{"key":"R6-3-20210131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/135965350400900312","article-title":". Infrequent transmission of HIV-1 drug-resistant variants.","volume":"9","author":"Yerly","year":"2004","journal-title":"Antivir Ther"},{"key":"R7-3-20210131","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/367989","article-title":". Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.","volume":"187","author":"Leigh Brown","year":"2003","journal-title":"J Infect Dis"},{"key":"R8-3-20210131","first-page":"29","article-title":". Prevalence and determinants of HIV-1 subtypes in Canada: enhancing routinely collected information through the Canadian HIV Strain and Drug Resistance Surveillance Program.","volume":"29","author":"Jayaraman","year":"2003","journal-title":"Can Commun Dis Rep"},{"key":"R9-3-20210131","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":". Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.","volume":"47","author":"Hirsch","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R10-3-20210131","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":". Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy.","volume":"5","author":"Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"R11-3-20210131","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/bmj.322.7294.1074","article-title":"Is transmitted drug resistance in HIV on the rise It seems so.","volume":"322","author":"Little","year":"2001","journal-title":"BMJ"},{"key":"R12-3-20210131","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1128\/JVI.02579-07","article-title":". Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.","volume":"82","author":"Little","year":"2008","journal-title":"J Virol"},{"key":"R13-3-20210131","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.","volume":"9","author":"Gazzard","year":"2008","journal-title":"HIV Med"},{"key":"R14-3-20210131","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002030-200102160-00003","article-title":"Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting.","volume":"15","year":"2001","journal-title":"AIDS"},{"key":"R15-3-20210131","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/QAI.0b013e3181e8c7b0","article-title":". Longitudinal phylogenetic surveillance identifies distinct patterns of cluster dynamics.","volume":"55","author":"Ragonnet-Cronin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-3-20210131","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/088922202753472874","article-title":". Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence.","volume":"18","author":"Parekh","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R17-3-20210131","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":". Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.","volume":"50","author":"Woods","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R18-3-20210131","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/molbev\/msn083","article-title":"jModelTest: phylogenetic model averaging.","volume":"25","author":"Posada","year":"2008","journal-title":"Mol Biol Evol"},{"key":"R19-3-20210131","doi-asserted-by":"crossref","first-page":"e9490","DOI":"10.1371\/journal.pone.0009490","article-title":"FastTree 2approximately maximum-likelihood trees for large alignments.","volume":"5","author":"Price","year":"2010","journal-title":"PLoS One"},{"key":"R20-3-20210131","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/bioinformatics\/btp134","article-title":". The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance.","volume":"25","author":"Gifford","year":"2009","journal-title":"Bioinformatics"},{"key":"R21-3-20210131","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":". Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"R24-3-20210131","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/infdis\/jir550","article-title":". Transmission network parameters estimated from HIV sequences for a nationwide epidemic.","volume":"204","author":"Leigh Brown","year":"2011","journal-title":"J Infect Dis"},{"key":"R25-3-20210131","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/651951","article-title":"RD, von WV, Yerly S, et al.. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland.","volume":"201","year":"2010","journal-title":"J Infect Dis"},{"key":"R26-3-20210131","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ncomms1325","article-title":". A novel methodology for large-scale phylogeny partition.","volume":"2","author":"Prosperi","year":"2011","journal-title":"Nat Commun"},{"key":"R27-3-20210131","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/jac\/dks287","article-title":". Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002-09.","volume":"67","author":"Burchell","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R28-3-20210131","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/JVI.78.2.603-611.2004","article-title":". Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.","volume":"78","author":"Collins","year":"2004","journal-title":"J Virol"},{"key":"R29-3-20210131","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/JCM.00605-10","article-title":". Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.","volume":"48","author":"Dykes","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R30-3-20210131","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/01.aids.0000131391.91468.ff","article-title":". Persistence of primary drug resistance among recently HIV-1 infected adults.","volume":"18","author":"Barbour","year":"2004","journal-title":"AIDS"},{"key":"R31-3-20210131","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/01.aids.0000199820.47703.a0","article-title":". HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.","volume":"20","author":"Ghosn","year":"2006","journal-title":"AIDS"},{"key":"R32-3-20210131","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00126334-200102010-00006","article-title":". Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.","volume":"26","author":"Briones","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R33-3-20210131","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMoa013552","article-title":". Antiretroviral-drug resistance among patients recently infected with HIV.","volume":"347","author":"Little","year":"2002","journal-title":"N Engl J Med"},{"key":"R34-3-20210131","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.qai.0000196666.16616.fe","article-title":". A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program.","volume":"42","author":"Jayaraman","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-3-20210131","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":". Differential persistence of transmitted HIV-1 drug resistance mutation classes.","volume":"203","author":"Jain","year":"2011","journal-title":"J Infect Dis"},{"key":"R36-3-20210131","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":". Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"R37-3-20210131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa041305","article-title":". Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.","volume":"351","author":"Jourdain","year":"2004","journal-title":"N Engl J Med"},{"key":"R38-3-20210131","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/655397","article-title":"Minority variants of drug-resistant HIV.","volume":"202","author":"Gianella","year":"2010","journal-title":"J Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e3182a4b991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T11:59:10Z","timestamp":1688385550000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201312150-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,15]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3182a4b991","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,15]]}}}